CITADEL ADVISORS LLC 13D and 13G filings for Zentalis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:20 pm Sale | 2024-09-30 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | CITADEL ADVISORS LLC | 2,737,221 3.900% | -1,001,261 (-26.78%) | Filing |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | CITADEL ADVISORS LLC | 3,738,482 5.300% | -101,347 (-2.64%) | Filing |
| 2023-11-17 5:12 pm Purchase | 2023-11-07 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | CITADEL ADVISORS LLC | 3,839,829 5.400% | 2,335,959 (+155.33%) | Filing |
| 2021-02-16 4:30 pm Sale | 2020-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | CITADEL ADVISORS LLC | 1,503,870 3.700% | -626,094 (-29.39%) | Filing |
| 2020-04-09 4:01 pm Purchase | 2020-04-03 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | CITADEL ADVISORS LLC | 2,129,964 5.900% | 2,129,964 (New Position) | Filing |